iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

February 28, 2024

https://www.globenewswire.com/news-release/2024/02/28/2836934/0/en/iCAD-Highlights-Promising-Clinical-Data-Demonstrating-Ability-to-Reduce-Breast-Interval-Cancer-Rates-and-Decrease-Recall-Rates-at-ECR-2024-Showcases-Additional-Platform-Offerings.html

NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, Feb 28 – March 3, 2024. The Company also announced it will highlight a new release for its AI-powered ProFound Detection solution while showcasing its full Breast Health Suite in booth X1 AI-35.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.